dopamine agents

Summary

Summary: Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Top Publications

  1. pmc Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans
    Mathias Pessiglione
    Wellcome Department of Imaging Neuroscience, 12 Queen Square, London WC1N 3BG, UK
    Nature 442:1042-5. 2006
  2. ncbi Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET
    Roshan Cools
    Department of Experimental Psychology, University of Cambridge, Cambridge, UK
    Brain 125:584-94. 2002
  3. pmc Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition
    J B Rowe
    University of Cambridge Department of Clinical Neurosciences, Cambridge, CB2 7EF, UK
    Brain 131:2094-105. 2008
  4. ncbi Habitual versus goal-directed action control in Parkinson disease
    Sanne de Wit
    Department of Psychology, Amsterdam Center for Study of Adaptive Control in Brain and Behavior Acacia, University of Amsterdam, Roeterstraat 15, 1018 WB, The Netherlands
    J Cogn Neurosci 23:1218-29. 2011
  5. ncbi Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease
    Masato Asanuma
    Department of Brain Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700 8558, Japan
    Neurotox Res 5:165-76. 2003
  6. pmc Action controls dopaminergic enhancement of reward representations
    Marc Guitart-Masip
    Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University College London, London WC1N 3BG, United Kingdom
    Proc Natl Acad Sci U S A 109:7511-6. 2012
  7. pmc Inverted-U-shaped dopamine actions on human working memory and cognitive control
    Roshan Cools
    Department of Psychiatry, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Biol Psychiatry 69:e113-25. 2011
  8. ncbi Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet Neurol 5:677-87. 2006
  9. ncbi Neurochemical findings in the MPTP model of Parkinson's disease
    N Schmidt
    Institute of Pharmacology and Toxicology, Faculty of Pharmacy, University of Marburg, Federal Republic of Germany
    J Neural Transm 108:1263-82. 2001
  10. pmc Mitochondrial fragmentation is involved in methamphetamine-induced cell death in rat hippocampal neural progenitor cells
    Changhai Tian
    The Laboratory of Neurotoxicology at the Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, Nebraska, USA
    PLoS ONE 4:e5546. 2009

Detail Information

Publications228 found, 100 shown here

  1. pmc Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans
    Mathias Pessiglione
    Wellcome Department of Imaging Neuroscience, 12 Queen Square, London WC1N 3BG, UK
    Nature 442:1042-5. 2006
    ..We conclude that dopamine-dependent modulation of striatal activity can account for how the human brain uses reward prediction errors to improve future decisions...
  2. ncbi Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET
    Roshan Cools
    Department of Experimental Psychology, University of Cambridge, Cambridge, UK
    Brain 125:584-94. 2002
    ..These data suggest that L-dopa ameliorates high-level cognitive deficits in Parkinson's disease by inducing relative blood flow changes in the right dorsolateral prefrontal cortex...
  3. pmc Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition
    J B Rowe
    University of Cambridge Department of Clinical Neurosciences, Cambridge, CB2 7EF, UK
    Brain 131:2094-105. 2008
    ..We discuss the implications for investigation and optimal treatment of this common condition at different stages of disease...
  4. ncbi Habitual versus goal-directed action control in Parkinson disease
    Sanne de Wit
    Department of Psychology, Amsterdam Center for Study of Adaptive Control in Brain and Behavior Acacia, University of Amsterdam, Roeterstraat 15, 1018 WB, The Netherlands
    J Cogn Neurosci 23:1218-29. 2011
    ..If anything our results suggest a disease severity-dependent deficit in goal-directed behavior. These results are discussed in the context of Parkinson disease and the neurobiology of habitual and goal-directed behavior...
  5. ncbi Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease
    Masato Asanuma
    Department of Brain Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700 8558, Japan
    Neurotox Res 5:165-76. 2003
    ....
  6. pmc Action controls dopaminergic enhancement of reward representations
    Marc Guitart-Masip
    Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University College London, London WC1N 3BG, United Kingdom
    Proc Natl Acad Sci U S A 109:7511-6. 2012
    ..These findings highlight a key role for dopamine in the generation of appetitively motivated actions...
  7. pmc Inverted-U-shaped dopamine actions on human working memory and cognitive control
    Roshan Cools
    Department of Psychiatry, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Biol Psychiatry 69:e113-25. 2011
    ..Manipulating DA will thus have paradoxical consequences for distinct cognitive control processes, depending on distinct basal or optimal levels of DA in different brain regions...
  8. ncbi Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet Neurol 5:677-87. 2006
    ..The current challenge is to develop a long-acting oral formulation of levodopa that provides clinical benefits but avoids motor complications...
  9. ncbi Neurochemical findings in the MPTP model of Parkinson's disease
    N Schmidt
    Institute of Pharmacology and Toxicology, Faculty of Pharmacy, University of Marburg, Federal Republic of Germany
    J Neural Transm 108:1263-82. 2001
    ..In this review we focus on the MPTP mouse model which is easy practicable and widely used in neuroscience research and draw comparisons to the human pathology in PD...
  10. pmc Mitochondrial fragmentation is involved in methamphetamine-induced cell death in rat hippocampal neural progenitor cells
    Changhai Tian
    The Laboratory of Neurotoxicology at the Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, Nebraska, USA
    PLoS ONE 4:e5546. 2009
    ..This provides a potential mechanism for METH-related neurodegenerative disorders, and also provides insight into therapeutic strategies for the neurodegenerative effects of METH...
  11. ncbi Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease
    Simon J G Lewis
    Cambridge Centre for Brain Repair, Forvie Site, Addenbrooke s Hospital, Cambridge CB2 2PY, UK
    Neuropsychologia 43:823-32. 2005
    ..These results confirm that working memory deficits in PD are both psychologically specific and related to dopamine depletion. It is anticipated that greater understanding of these mechanisms will lead to future therapeutic improvements...
  12. ncbi Medication-related impulse control and repetitive behaviors in Parkinson disease
    Valerie Voon
    National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Dr, Bldg 10, Room 5S213, Bethesda, MD 20892 1428, USA
    Arch Neurol 64:1089-96. 2007
    ..The study of these behaviors allows not only improved clinical management but also greater insight into a biologically mediated complex behavioral model...
  13. pmc Dopaminergic drugs modulate learning rates and perseveration in Parkinson's patients in a dynamic foraging task
    Robb B Rutledge
    Center for Neural Science, New York University, New York, New York 10003, USA
    J Neurosci 29:15104-14. 2009
    ....
  14. ncbi Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism
    Michael J Frank
    Department of Psychology and Program in Neuroscience, University of Arizona, Tucson, AZ 85721, USA
    Science 318:1309-12. 2007
    ..These findings implicate independent mechanisms leading to impulsivity in treated Parkinson's patients and were predicted by a single neurocomputational model of the basal ganglia...
  15. ncbi Antinociceptive mechanism of L-DOPA
    Takao Shimizu
    Department of Pharmacology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890 8544, Japan
    Pain 110:246-9. 2004
    ..These results suggest that L-DOPA relieves pain after conversion to dopamine, with the dopamine sedating pain transmission by way of the dopamine D2 receptor...
  16. ncbi Dopaminergic-based pharmacotherapies for depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 16:391-402. 2006
    ..In the present article we will briefly review studies focusing on the role of dopamine in depression followed by a comprehensive review of pharmacotherapies for depression with pro-dopaminergic activity...
  17. ncbi Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study
    P Del Dotto
    Department of Neuroscience, Neurology Section, University of Pisa, Via Roma 67, 56100 Pisa, Italy
    Mov Disord 16:515-20. 2001
    ..This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations...
  18. pmc Dopamine enhances expectation of pleasure in humans
    Tali Sharot
    Wellcome Trust Centre for Neuroimaging, University College London, London WC1N 3BG, UK
    Curr Biol 19:2077-80. 2009
    ..These findings provide the first direct evidence for the role of dopamine in the modulation of subjective hedonic expectations in humans...
  19. pmc Dopamine and performance in a reinforcement learning task: evidence from Parkinson's disease
    Tamara Shiner
    Wellcome Trust Centre for Neuroimaging, UCL, London, WC1N 3BG, UK
    Brain 135:1871-83. 2012
    ....
  20. pmc Methamphetamine toxicity and its implications during HIV-1 infection
    Peter S Silverstein
    Division of Pharmacology and Toxicology, School of Pharmacy, University of Missouri Kansas City, Kansas City, MO 64108, USA
    J Neurovirol 17:401-15. 2011
    ....
  21. ncbi Distinguishing whether dopamine regulates liking, wanting, and/or learning about rewards
    Siobhan Robinson
    Neurobiology and Behavior Program, University of Washington, Seattle, WA, USA
    Behav Neurosci 119:5-15. 2005
    ....
  22. ncbi Prospective prevalence of pathologic gambling and medication association in Parkinson disease
    V Voon
    Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 1428, USA
    Neurology 66:1750-2. 2006
    ..4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist...
  23. ncbi Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD
    F Bibbiani
    ETB, NINDS, National Institutes of Health, Bethesda, MD 20892, USA
    Exp Neurol 196:422-9. 2005
    ....
  24. ncbi Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
    Pierre N Tariot
    Department of Psychiatry, University of Rochester Medical Center, Monroe Community Hospital, Rochester, NY 14620, USA
    JAMA 291:317-24. 2004
    ....
  25. ncbi Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial
    Peter Schnuelle
    University Medical Centre Mannheim, 5th Department of Medicine, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    JAMA 302:1067-75. 2009
    ..Kidney graft function after transplantation can be improved through pharmacological donor pretreatment to limit organ injury from cold preservation...
  26. ncbi Dopamine and NMDA systems modulate long-term nociception in the rat anterior cingulate cortex
    Alberto Lopez-Avila
    Laboratorio de Neurofisiología Integrativa, Subdirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente, Camino a Xochimilco, 101 San Lorenzo Huipulco Tlalpan, México DF cp 14370, Mexico
    Pain 111:136-43. 2004
    ..The present study suggests an interaction between dopaminergic and glutamatergic systems within the ACC in the genesis and maintenance of long-term nociception...
  27. pmc Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study
    M E L Arbouw
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Universiteit Utrecht, P O BOX 80082, 3508 TB, Utrecht, The Netherlands
    Osteoporos Int 22:2197-204. 2011
    ..Concomitant use of antidepressants further increased this risk. Fracture risk assessment may be warranted in elderly users of dopaminergic drugs...
  28. ncbi Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study
    Fabrizio Stocchi
    Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy
    Ann Neurol 68:18-27. 2010
    ....
  29. ncbi In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability
    Mahmoud M Iravani
    Neurodegenerative Disease Research Group, School of Health and Biomedical Sciences, King s College, London, United Kingdom
    J Pharmacol Exp Ther 319:1225-34. 2006
    ..These data suggest that selective 5-HT(1a) agonists do not provide an effective means of suppressing levodopa-induced dyskinesia, except with worsening of parkinsonism...
  30. pmc Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways
    F Papaleo
    Clinical Brain Disorders Branch, Genes, Cognition and Psychosis Program, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 17:85-98. 2012
    ..These results elucidate dysbindin's modulation of D2-related behavior, cortical activity and mPFC CaMK components, implicating cellular and molecular mechanisms of the association of dysbindin with psychosis...
  31. ncbi Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice
    Stephanie Weiss
    INSERM U513, Créteil F 94000, France
    Neuropharmacology 52:1496-508. 2007
    ..This study may provide potential leads for the use of nicotine or combined nicotinic agonists for the therapy of psychiatric disorders...
  32. ncbi Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha
    Krishnan Sriram
    Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, WV 26505, USA
    J Neurochem 96:706-18. 2006
    ..These findings support the hypothesis that TNF-alpha may play a role in the selective vulnerability of the nigrostriatal pathway associated with dopaminergic neurotoxicity and perhaps Parkinson's disease...
  33. pmc Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP
    William Dauer
    Department of Neurology, Columbia University, New York, NY 10027, USA
    Proc Natl Acad Sci U S A 99:14524-9. 2002
    ....
  34. ncbi Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands
    R Cools
    Department of Experimental Psychology, University of Cambridge, Downing Street, Cambridge CB2 3EB, UK
    Cereb Cortex 11:1136-43. 2001
    ..Hence, DA-ergic medication improves or impairs cognitive performance depending on the nature of the task and the basal level of DA function in underlying cortico-striatal circuitry...
  35. pmc Rescue of dopamine transporter function in hypoinsulinemic rats by a D2 receptor-ERK-dependent mechanism
    W Anthony Owens
    Department of Physiology and Pharmacology, The University of Texas Health Science Center, San Antonio, TX 78229, USA
    J Neurosci 32:2637-47. 2012
    ....
  36. ncbi Subthalamic deep brain stimulation and impulse control in Parkinson's disease
    T D Hälbig
    Federation de Neurologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Eur J Neurol 16:493-7. 2009
    ..The purpose of this study was to assess various measures of impulse control in PD patients with STN DBS in comparison to patients receiving medical therapy...
  37. ncbi Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms
    Mark A Cervinski
    Department of Biochemistry and Molecular Biology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58202, USA
    J Biol Chem 280:40442-9. 2005
    ..The finding that DAT phosphorylation is stimulated by amphetamines reveals a previously unknown effect of these drugs that is not produced by cocaine and may be related to reinforcement...
  38. ncbi Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice
    Shuei Sugama
    Harold L Dorris Neurological Research Center, Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Brain Res 964:288-94. 2003
    ..The present study suggests that age-related microglial activation in the SN may be relevant to the higher susceptibility to MPTP neurotoxicity in older mice...
  39. ncbi The role of dopamine in learning, memory, and performance of a water escape task
    Victor H Denenberg
    Department of Biochemistry, University of Washington, Box 357370, Seattle, WA 98195 7370, USA
    Behav Brain Res 148:73-8. 2004
    ....
  40. pmc Dopamine regulates angiogenesis in normal dermal wound tissues
    Saurav Shome
    Department of Signal Transduction and Biogenic Amines, Chittaranjan National Cancer Institute, Kolkata, India
    PLoS ONE 6:e25215. 2011
    ....
  41. ncbi Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems
    A Carlsson
    Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden
    J Neural Transm 109:777-87. 2002
  42. ncbi Linking nucleus accumbens dopamine and blood oxygenation
    Brian Knutson
    Department of Psychology, Stanford University, Building 420, Jordan Hall, Stanford, CA 94305, USA
    Psychopharmacology (Berl) 191:813-22. 2007
    ..However, the physiological relationship between dopamine release and BOLD signal increases in the NAcc has not yet been established...
  43. ncbi Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease
    G E Meredith
    Department of Cellular and Molecular Pharmacology, Chicago Medical School, Finch University of Health Sciences, 3333 Green Bay Road, North Chicago, IL 60064, USA
    Brain Res 956:156-65. 2002
    ..They further suggest that defective protein degradation rather than altered gene expression underlies deposition of alpha-synuclein and that abundant lysosomal compartments are present to seal off the potentially toxic material...
  44. ncbi Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor
    J R Bunzow
    Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, Oregon 97201, USA
    Mol Pharmacol 60:1181-8. 2001
    ....
  45. ncbi Role of dopamine in the motivational and cognitive control of behavior
    Roshan Cools
    F C Donders Centre for Cognitive Neuroimaging, Radboud University Nijmegen, The Netherlands
    Neuroscientist 14:381-95. 2008
    ....
  46. pmc Evidence for neurogenesis in the adult mammalian substantia nigra
    Ming Zhao
    Departments of Neuroscience, Cell and Molecular Biology, Medical Nobel Institute, and Woman and Child Health, Karolinska Institute, SE 171 77 Stockholm, Sweden
    Proc Natl Acad Sci U S A 100:7925-30. 2003
    ....
  47. ncbi Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum
    Krystyna Gołembiowska
    Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, Kraków 31 343, Poland
    Neurotox Res 15:155-66. 2009
    ..Summing up, A(2A) antagonists, used as a supplement of L: -DOPA therapy, depending on the dose used, may have a beneficial or adverse effect on ongoing neurodegenerative processes and accompanying oxidative stress...
  48. ncbi Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP
    Zhizhong Dong
    Institute of Molecular Biology, University of Zurich, CH 8057 Zurich, Switzerland
    J Neurobiol 53:1-10. 2002
    ....
  49. pmc Methamphetamine induces dopamine D1 receptor-dependent endoplasmic reticulum stress-related molecular events in the rat striatum
    Subramaniam Jayanthi
    Molecular Neuropsychiatry Research Branch, National Institute of Drug Abuse, National Institutes of Health NIH Department of Health and Human Services DHHS, Intramural Research Program, Baltimore, MD, USA
    PLoS ONE 4:e6092. 2009
    ..Our data also suggest that METH-induced toxicity might be a useful model to dissect molecular mechanisms involved in ER stress-dependent events in the rodent brain...
  50. pmc Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors
    Wenjing Xu
    Department of Biological Sciences, Hunter College of the City University of New York, New York, NY 10021, USA
    Synapse 58:110-21. 2005
    ..Moreover, since blockade of either receptor subtype protected from METH, the activity of both DA receptor subtypes is required for the induction of toxicity by METH in the striatum...
  51. ncbi Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice
    E Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite de Bordeaux II, Bordeaux Cedex, France
    Synapse 38:363-8. 2000
    ....
  52. pmc Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
    Christine Konradi
    Laboratory of Neuroplasticity, McLean Hospital, Belmont, MA 02478, USA
    Neurobiol Dis 17:219-36. 2004
    ..Some basic maintenance chores such as ribosome protein biosynthesis were downregulated, possibly a response to expended ATP levels...
  53. ncbi An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior
    Jean Martin Beaulieu
    Department of Cell Biology, Center for Models of Human Disease, Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cell 122:261-73. 2005
    ....
  54. ncbi The basal ganglia in Parkinson's disease: current concepts and unexplained observations
    Jose A Obeso
    Departments of Neurology, Neurophysiology and Neurosurgery, Clinica Universitaria and Medical School, Neuroscience Centre, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Ann Neurol 64:S30-46. 2008
    ..The growing understanding of the complexity of the normal BG and the changes induced by DA depletion should guide the development of more efficacious therapies for Parkinson's disease...
  55. ncbi A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets
    Mahmoud M Iravani
    Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King s College, London SE1 1UL, UK
    Eur J Neurosci 21:841-54. 2005
    ..In addition, these partially lesioned animals did not respond to acute treatment with L-DOPA. This primate partial lesions model may be useful for examining potential neuroprotective or neurorestorative agents for PD...
  56. ncbi MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons
    N W Kowall
    Geriatric Research Education Clinical Center, Veterans Affairs Medical Center, Bedford, MA 01730, USA
    Neuroreport 11:211-3. 2000
    ..alpha-Synuclein aggregation induced by MPTP models the early stages of Lewy body formation and may be a fundamental step in the evolution of neuronal degeneration in PD...
  57. pmc Mechanisms of methamphetamine-induced dopaminergic neurotoxicity
    Evan L Riddle
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    AAPS J 8:E413-8. 2006
    ..This review will describe the current understanding of how high-dose METH administration leads to the production of these toxic reactive species and consequent permanent dopaminergic deficits...
  58. ncbi Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300)
    Jean Marc Orgogozo
    CHU Pellegrin, Bordeaux, France
    Stroke 33:1834-9. 2002
    ....
  59. ncbi Neurotoxicity of MPTP
    T Fukuda
    Department of Neuroscience, Research Center for Medical Science, The Jikei University School of Medicine, Tokyo, Japan
    Neuropathology 21:323-32. 2001
    ..I would like to highlight the significance of re-examination of environmental factors in the etiology of Parkinson's disease...
  60. ncbi A 6-month, open-label study of memantine in patients with frontotemporal dementia
    Janine Diehl-Schmid
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany
    Int J Geriatr Psychiatry 23:754-9. 2008
    ..To evaluate safety and effects on cognition and behavior of memantine 20 mg/day in the treatment of patients with frontotemporal dementia (FTD)...
  61. ncbi Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP
    David D Song
    Neurology Service, VA San Diego Healthcare System, San Diego, CA 92161 9127, USA
    Exp Neurol 186:158-72. 2004
    ..These findings support the potential involvement of alpha-S expression in the vulnerability of SN neurons to toxicity from mitochondrial complex I inhibitors and the subsequent development of neurodegenerative pathology...
  62. ncbi Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts
    S Z Imam
    Neurochemistry Laboratory Division of Neurotoxicology, HFT-132, National Center for Toxicological Research/FDA, 3900 NCTR Rd, Jefferson, AR 72079, USA
    Ann N Y Acad Sci 939:366-80. 2001
    ..These antioxidants and decomposition catalysts may have therapeutic potential in the treatment of psychostimulant addictions...
  63. ncbi An evaluation of the reinforcing effects of memantine in cocaine-dependent humans
    Suzanne K Vosburg
    College of Physicians and Surgeons of Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    Drug Alcohol Depend 79:257-60. 2005
    ..Memantine was not reinforcing and subjective-effects ratings were not altered as a function of dose. Results suggest that these doses of memantine do not have abuse liability in cocaine-dependent individuals...
  64. ncbi The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum
    Veronica Sanchez
    Departamento de Farmacologia and Facultad de Medicina Instituto de Bioquimica CSIC UCM, Facultad de Farmacia, Universidad Complutense, Madrid, Spain
    J Neurochem 85:515-24. 2003
    ..These data indicate that both the reduction of NF68 immunoreactivity and the loss of dopamine concentration are due to an oxidative stress process mediated by reactive nitrogen species, and are not due to changes in body temperature...
  65. ncbi PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences
    S Thobois
    Sobell Department of Motor Neurosciences and Movement Disorders, Institute of Neurology, London, UK
    Neuroimage 23:1-16. 2004
    ..Interestingly, dopaminergic medications or surgical therapy reverse such abnormalities of brain activation...
  66. ncbi Memantine in vascular dementia
    Hans Jörg Möbius
    Merz Co, Frankfurt M, Germany
    Int Psychogeriatr 15:207-13. 2003
    ..In these trials, memantine at a dose of 10 mg b.i.d. was safe and very well tolerated with a frequency of dropouts due to adverse events that was close to placebo...
  67. ncbi A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil
    Christopher H van Dyck
    Department of Psychiatry, Yale University, New Haven, Connecticut 06510, USA
    Am J Geriatr Psychiatry 14:428-37. 2006
    ..The objective of this study was to examine the clinical utility of memantine for moderate-to-severe Alzheimer disease (AD) using responder analyses...
  68. ncbi Observations from a 14-week open-label trial with memantine suggest variable response on behavioral symptoms and cognition, depending on former treatment of AD
    Paul L J Dautzenberg
    Int Psychogeriatr 18:179-81. 2006
  69. ncbi Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration
    Robert E Drolet
    The Neuroscience Program, Michigan State University, B 436 Life Sciences Building, East Lansing, MI 48824, USA
    Neurotoxicology 25:761-9. 2004
    ....
  70. ncbi The restless legs syndrome
    Claudia Trenkwalder
    Paracelsus Elena Klinik, Centre of Parkinsonism and Movement Disorders, Kassel, Germany
    Lancet Neurol 4:465-75. 2005
    ..Various other drugs, such as opioids, gabapentin, and benzodiazepines, provide alternative treatment possibilities...
  71. ncbi Memantine fails to facilitate partial cigarette deprivation in smokers--no role of Memantine in the treatment of nicotine dependency?
    N Thuerauf
    Department of Psychiatry and Psychotherapy, University of Erlangen Nurnberg, Erlangen, Germany
    J Neural Transm 114:351-7. 2007
    ..Memantine failed to facilitate smoking reduction and did not influence the perception of nicotine with the exception of a weak reduction of olfactory intensity estimates reaching statistical significance for one nicotine enantiomer only...
  72. ncbi Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies
    Gordon K Wilcock
    From the Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Headington, UK
    J Clin Psychiatry 69:341-8. 2008
    ..The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer's disease exhibiting behavioral symptoms of agitation/aggression or psychosis at baseline...
  73. ncbi Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia
    M Smeyne
    Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee 38015, USA
    Glia 34:73-80. 2001
    ..The identification of glia as the critical cell type in the genesis of experimental Parkinsonism provides a target for the development of new anti-parkinsonian therapies...
  74. ncbi Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study
    S Bakchine
    Hospital Maison Blanche, INSERM EA 3797 Department of Neurology, Reims University Hospital, Reims, France
    J Alzheimers Dis 13:97-107. 2008
    ..Memantine was well tolerated with an adverse event profile similar to placebo. The data presented support the efficacy of memantine in mild to moderate AD...
  75. ncbi Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence
    Leea H Muhonen
    Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland
    J Clin Psychiatry 69:392-9. 2008
    ....
  76. ncbi Augmentation of the restless legs syndrome with carbidopa/levodopa
    R P Allen
    Department of Neurology, Johns Hopkins School of Medicine, Bayview Medical Center, Baltimore, Maryland, USA
    Sleep 19:205-13. 1996
    ..This augmentation was severe enough to require medication change for 50% of the RL patients and 13% of PLMS patients. Augmentation resolved with cessation of the medication and could be minimized by keeping the dose low...
  77. ncbi Augmentation as a treatment complication of restless legs syndrome: concept and management
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
    Mov Disord 22:S476-84. 2007
    ..The present article reviews our current knowledge on clinical diagnosis, evaluation, pathophysiology, and treatment recommendations for this condition...
  78. ncbi Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease
    Roy W Jones
    Research Institute for the Care of the Elderly RICE, Bath, UK
    Int J Geriatr Psychiatry 22:258-62. 2007
    ..To assess the safety and tolerability of three different dosing schedules of memantine in patients with moderate to severe Alzheimer's disease (AD)...
  79. ncbi Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity
    David M Thomas
    Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA
    J Neurochem 109:1745-55. 2009
    ..Recruitment of the NAc as a target of METH neurotoxicity by alterations in DA homeostasis is significant in light of the important roles played by this brain structure...
  80. ncbi Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment
    Howard H Feldman
    Division of Neurology, University of British Columbia, Vancouver, BC, Canada
    Alzheimer Dis Assoc Disord 20:263-8. 2006
    ..These post hoc analyses in moderate-to-severe AD patients receiving stable donepezil treatment suggest that memantine may impact overall functional levels, and some of the cognitive processing underlying ADL performance...
  81. pmc Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication
    Leea H Muhonen
    National Public Health Institute, Department of Mental Health and Alcohol Research, Finland
    Subst Abuse Treat Prev Policy 3:20. 2008
    ....
  82. ncbi Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis
    Frederick A Schmitt
    Department of Neurology, University of Kentucky Medical Center, Sanders Brown Center on Aging, Lexington, KY 40536, USA
    Alzheimer Dis Assoc Disord 20:255-62. 2006
    ....
  83. ncbi Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system
    A Abeliovich
    Department of Neurology, University of California, San Francisco 94143, USA
    Neuron 25:239-52. 2000
    ..These findings support the hypothesis that alpha-Syn is an essential presynaptic, activity-dependent negative regulator of DA neurotransmission...
  84. ncbi The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels
    Birgit Frauscher
    Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Sleep Med 10:611-5. 2009
    ..The aim of the study was to prospectively examine all patients with a diagnosis of RLS consulting a sleep disorders clinic and to assess RLS severity and augmentation and their associations, including ferritin levels...
  85. pmc Feeding behavior in dopamine-deficient mice
    M S Szczypka
    Howard Hughes Medical Institute, Department of Biochemistry, University of Washington, Seattle, WA 98195 7370, USA
    Proc Natl Acad Sci U S A 96:12138-43. 1999
    ..Therefore, DA-/- mice can execute behaviors necessary to seek and ingest food, but they do not eat enough to survive...
  86. ncbi Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats
    Laura E Bianco
    Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania 16802, USA
    J Neurochem 106:205-15. 2008
    ..These experiments provide new evidence that ID results in altered synthesis and functioning of DAT and perhaps suggests some compensatory changes in NE metabolism...
  87. ncbi l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
    H K Holmer
    Research Services, Neurocytology Laboratory, VA Medical Center, Portland, OR 97239, USA
    Neuroscience 136:333-41. 2005
    ....
  88. ncbi The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias
    Wei Li Kuan
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    Neurobiol Dis 25:594-608. 2007
    ..These results suggest that an A9 dopaminergic neuron-enriched transplant may be the key to an effective PD cell replacement therapy through normalisation of the altered striatal expression of Cdk5/DARPP-32...
  89. ncbi Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons
    Jin H Son
    Laboratory of Molecular Neurobiology, The W M Burke Medical Research Institute, White Plains, New York 10605, USA
    J Neurochem 94:1040-53. 2005
    ..These data suggest that a threshold level of Septin 5 accumulation is required for DAergic cell loss and that l-DOPA-responsive motor deficits can occur even in the presence of elevated DA...
  90. ncbi Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients
    Andreas Heinz
    Central Institute of Mental Health, Mannheim, Germany
    Am J Psychiatry 162:1515-20. 2005
    ..In this study, positron emission tomography (PET) was used to compare dopamine synthesis capacity in the striatum in alcoholic patients and healthy comparison subjects...
  91. ncbi Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum
    Krystyna Gołembiowska
    Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31 343 Krakow, Poland
    Brain Res 998:208-17. 2004
    ..These observations might be of relevance, considering the use of selective A2A antagonists as potential supplements to L-DOPA therapy of Parkinson's disease...
  92. pmc Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease
    Tatyana D Sotnikova
    Department of Cell Biology, Center for Models of Human Disease, Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina, USA
    PLoS Biol 3:e271. 2005
    ..Identification of dopamine transporter- and dopamine-independent locomotor actions of amphetamines suggests a novel paradigm in the search for prospective anti-Parkinsonian drugs...
  93. ncbi Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa derived extracellular dopamine in dopamine-denervated rat striatum
    Przemyslaw Nowak
    Department of Pharmacology, Medical University of Silesia, 41 808 Zabrze, Poland
    Neurotox Res 13:231-40. 2008
    ..Consequently, the histaminergic system represents a viable target for modulating the effectiveness of L-DOPA therapy in Parkinson's disease...
  94. ncbi Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation
    Tetsuya Maeda
    Department of Neurology, Research Institute for Brain and Blood Vessels, 6 10 Senshu Kubota machi, Akita 010 0874, Japan
    Neurosci Lett 433:255-8. 2008
    ..These findings suggest that the proliferation of glial cells in the striatum is the response to the loss of dopaminergic terminals but the glial cells do not compensate for the lost dopaminergic terminals...
  95. ncbi Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study
    Taro Nimura
    Department of Neurosurgery, Miyagi National Hospital, Japan
    J Neurosurg 103:968-73. 2005
    ..As part of an inquiry into the mechanism of STN DBS, the authors measured synaptic dopamine levels in the striatum by performing positron emission tomography (PET) with [11C]raclopride...
  96. ncbi Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease
    Moran Weinberger
    Department of Physiology, Med Sci Building 3302, 1 King s College Circle, University of Toronto, Toronto, Ontario M5S 1A8, Canada
    J Neurophysiol 96:3248-56. 2006
    ..The study also suggests that LFP beta oscillatory activity is generated largely within the dorsal portion of the STN and can produce synchronous oscillatory activity of the local neuronal population...
  97. ncbi Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata
    Noriko Yamamoto
    Department of Anatomy and Neurobiology, Boston University School of Medicine, 715 Albany Street, Room L1001, Boston, MA 02118, USA
    Brain Res 1123:196-200. 2006
    ..These results show that the subchronic administration of L-DOPA results in a sensitization of enhanced extracellular GABA levels in the SNr...
  98. ncbi Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition
    F Stocchi
    IRCCS San Raffaele Pisana, Rome, Italy
    Neurology 67:S24-9. 2006
    ..These hypotheses are under investigation and will pursue confirmation in controlled clinical trials...
  99. ncbi Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration
    Virgili Perez
    Laboratori de Neuropsicofarmacologia, Institut de Recerca de l Hospital de la Santa Creu i de Sant Pau, Avgda St Antoni M a Claret, 167, 08025 Barcelona, Spain
    Eur J Pharmacol 576:83-90. 2007
    ..These findings suggest that additional noradrenergic denervation selectively decreases the motor threshold to l-DOPA treatment without modifying the magnitude or the pattern of the motor response to adenosinergic antagonism...
  100. ncbi Viral restoration of dopamine signaling to the dorsal striatum restores instrumental conditioning to dopamine-deficient mice
    Siobhan Robinson
    Graduate Program in Neurobiology and Behavior, Howard Hughes Medical Institute, University of Washington, Seattle, WA, 98195, USA
    Psychopharmacology (Berl) 191:567-78. 2007
    ..Instrumental responding was evaluated to determine whether mice lacking dopamine [dopamine-deficient mice (DD mice)] could learn to preferentially press a visually cued, active lever for food reward over an inactive lever...
  101. ncbi Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study
    N Pavese
    MRC Clinical Sciences Centre and Division of Neurosciences, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK
    Neurology 67:1612-7. 2006
    ..To evaluate the relationship between clinical improvement and in vivo synaptic dopamine (DA) release after a single oral dose of levodopa (LD) in patients with advanced Parkinson disease (PD)...

Research Grants63

  1. MONOAMINE AND HALLUCINOGEN EFFECTS ON RODENT BEHAVIOR
    Mark A Geyer; Fiscal Year: 2013
    ..Such information is critical to understand the consequences of the use of these compounds and to provide models of psychosis that could help identify novel therapeutic targets for neuropsychiatric disorders. ..
  2. A D1 Agonist for Working Memory Enhancement in the Schizophrenia Spectrum
    Larry J Siever; Fiscal Year: 2013
    ..3. SPD patients will show significant improvements on primary outcome variables on drug compared to placebo but not on comparison on perceptual (JLOT) and processing speed tasks (Trails A). ..
  3. The Role of 5-HT6 Receptors in Primary Neuronal Cilia
    John F Neumaier; Fiscal Year: 2013
    ..These experiments will create a platform for determining whether targeting cell signaling mechanisms in the cilia will offer new opportunities for developing therapeutics for addiction and other compulsive disorders. ..
  4. Dopaminergic modulation of dentritic excitability
    Srdjan D Antic; Fiscal Year: 2010
    ..abstract_text> ..
  5. Apathy in Alzheimer's Disease Methylphenidate Trial
    Paul B Rosenberg; Fiscal Year: 2010
    ..This study aims to develop a new treatment for apathy in AD that could decrease its debilitating consequences and reduce patients'dependency on caregivers, providing well-deserved relief to patients and their loved ones. ..
  6. A2AR/mGluR5 Antagonist Combination Antiparkinsonian Therapy in MPTP Monkeys
    James Bogenpohl; Fiscal Year: 2010
    ..So, an effective symptomatic treatment for PD that does not induce serious side effects could improve the quality of life of many thousands of PD patients worldwide. ..
  7. METHAMPHETAMINE ABUSE AND CORTICAL CELL INJURY
    JOHN FOSTER MARSHALL; Fiscal Year: 2012
    ..In aggregate, these experiments should provide a body of novel evidence concerning how methamphetamine addiction can alter cortical functions. ..
  8. Receptor trafficking profiles of clinically important dopaminergic drugs
    Jennifer L Whistler; Fiscal Year: 2013
    ....
  9. Signaling regulation in the striatum in Parkinson's disease
    Eugenia V Gurevich; Fiscal Year: 2013
    ..The studies will pave the way to development of novel therapeutic approaches to control motor deficits in Parkinsons'disease and complications of L-DOPA therapy. ..
  10. Nicotinic Modulation of Methamphetamine's Behavioral and Neurochemical Effects
    RAJEEV INDRAJIT DESAI; Fiscal Year: 2010
    ..The proposed research will lead to a greater understanding of the mechanisms responsible for methamphetamine addiction and may identify novel nicotinic targets to help combat methamphetamine addiction. ..
  11. Manipulating Gene Expression in the Dyskinesias of Parkinson's Disease
    Stella M Papa; Fiscal Year: 2013
    ..Furthermore, these studies will assess the clinical application of (FosB gene silencing as a therapeutic strategy in complicated Parkinson's disease. ..
  12. Imaging Dopamine Mediated Neurovascular Coupling
    Bruce Jenkins; Fiscal Year: 2010
    ..Finally, we will improve both our quantitative ability to acquire the data using higher contrast to noise techniques as well as model the signal changes using dopaminergic release and reuptake curves. ..
  13. Frontal Cortex and Executive Function
    MARK D'ESPOSITO; Fiscal Year: 2012
    ..Moreover, such knowledge may provide a foundation for developing cognitive and pharmacological therapies for treating the wide range of disorders characterized as deficits in executive control. ..
  14. Developmental Psychopharmacology of Antipsychotics
    JENNY WILEY; Fiscal Year: 2007
    ..This information will help to provide a more rational basis for making treatment decisions concerning children and adolescents who may benefit from treatment with an antipsychotic. [unreadable] [unreadable]..
  15. Feedback Learning and L-Dopa in Parkinson's Disease
    Mark Gluck; Fiscal Year: 2009
    ..This will allow doctors to identify optimal dosing and medication combinations for each individual patient that lead to enhanced motor and cognitive functioning. ..
  16. Brain plasticity and rehabilitation after stroke
    Steven C Cramer; Fiscal Year: 2013
    ..The candidate has long been committed to mentoring clinical scientists in patient-oriented research and looks forward to increasing this activity in the future. ..
  17. ADRENERGIC & CHOLINERGIC MECHANISMS IN GLAUCOMA THERAPY
    JON POLANSKY; Fiscal Year: 1993
    ....
  18. NON-NITROGEN AND NITROGEN CONTAINING DOPAMINE DRUGS
    Duane Miller; Fiscal Year: 1992
    ..4.To synthesize a set of formamidino, guanidino and thiourea analogs of DA, in order to investigate the overall importance of hydrogen bonding in the interaction of DAergic drugs with DAergic receptors...
  19. Effects of Coenzyme Q10 in Parkinson Disease-Phase 3
    M Flint Beal; Fiscal Year: 2010
    ..We will determine the mean plasma coenzyme Q10 levels at baseline and at visits 1, 8 and 16 months, and determine whether the mean correlates with reduction in worsening of the total UPDRS score. ..
  20. Semantic Network Flexibility Modulation/Autism Spectrum
    David Beversdorf; Fiscal Year: 2007
    ..OSU and my outside consultants are well equipped for my current and future research goals, with ongoing autism research, possible potential for future high-field fMRI, and strong neruoscience training. ..
  21. Macrophages and dopamine: a role in NeuroAIDS
    Peter Gaskill; Fiscal Year: 2009
    ....
  22. NUCLEUS ACCUMBENS INVOLVEMENT IN COCAINE REINFORCEMENT
    GREGORY MARK; Fiscal Year: 2002
    ..It is hoped that these results will further our understanding of the involvement of cholinergic mechanisms in drug-seeking and potentially to the development of clinically efficacious treatments for drug craving and relapse. ..
  23. MOTOR ACTIONS OF CANNABINOIDS IN A PARKINSONS MODEL
    CLARA SANUDO PENA; Fiscal Year: 2002
    ..Behavioral, biochemical, and physiological studies will be conducted in parallel to test this possibility. It will also help integrate the cannabinergic system with the current knowledge of basal ganglia physiology. ..
  24. BASAL GANGLIA CIRCUITRY IMMEDIATE EARLY GENE EXPRESSION
    David Wirtshafter; Fiscal Year: 2003
    ..Other studies will examine the effects of lesions within the basal ganglia on the IEG expression induced by systemic administration of dopaminergic drugs. ..
  25. KAINIC ACID AND STRIATAL DOPAMINE TURNOVER
    Robert Schwarcz; Fiscal Year: 1980
    ..This should prove particularly useful for studying unilateral disorders of the basal ganglia...
  26. SIGNALING MECHANISMS IN DOPAMINE RECEPTOR SYNERGISM
    Yuan Luo; Fiscal Year: 2007
    ..The findings might also yield new insights into the therapeutic mechanisms of dopamine agents that are used in diverse brain disorders, thus facilitating the future development of safer and more ..
  27. STRIATAL ORGANIZATION AND DOPAMINE RECEPTOR LOCALIZATION
    John Marshall; Fiscal Year: 2006
    ..The significance of this work derives both from its relevance to basal ganglia disorders such as Parkinson's disease and also because of its potential to elucidate the significance of the pallidostriatal circuitry. ..
  28. NOVEL COCAINE PHARMACOTHERAPIES: LAB STUDIES
    Margaret Haney; Fiscal Year: 2003
    ....
  29. Hypocretin, Histamine and the Restless Legs Syndrome
    Richard Allen; Fiscal Year: 2004
    ..Several RLS patients on treatment with dopamine agents report some problems with sleepiness they had not previously experienced and several also report marked ..
  30. Dopamine and Iron in Restless Legs Syndrome
    Christopher Earley; Fiscal Year: 2006
    ..Like Parkinson's disease, restless legs syndrome is exquisitely sensitive to dopamine agents and aggravated or precipitated by dopamine antagonists...
  31. REGULATION OF BRAIN PEPTIDE BIOSYTHESIS
    Michael Bannon; Fiscal Year: 1993
    ....
  32. PHARMACOLOGIC AND PHYSIOLOGIC MECHANISMS IN PARKINSONISM
    Joel Trugman; Fiscal Year: 1991
    ..Results of these studies should facilitate the rational use of available agents and suggest new pharmacologic strategies for the treatment of PD...
  33. GONADAL HORMONE INVOLVEMENT IN BRAIN ACTIVITY
    Jill Becker; Fiscal Year: 1990
    ..However, our understanding of how estrogen influences neural activity in the striatum is still very limited. It is necessary to better understand the basic mechanisms involved before all of the clinical applications will be appreciated...
  34. DOPAMINERGIC MECHANISMS IN NICOTINE ADDICTION
    Lisa Brauer; Fiscal Year: 2001
    ....
  35. MOLECULAR INTERACTIONS OF RGS2 WITH DOPAMINE RECEPTORS
    BONITA BLAKE; Fiscal Year: 2004
    ..abstract_text> ..
  36. GUSTATORY REWARD AND DOPAMINE IN THE NUCLEUS ACCUMBENS
    Andras Hajnal; Fiscal Year: 2003
    ..This knowledge is directly relevant to understanding the control of normal ingestive behavior and to the maladies related to this essential behavior, such as obesity, anorexia nervosa, bulimia nervosa, and binge eating disorder. ..
  37. STRIATAL SUBREGION SYSTEMS AND LOCOMOTION
    Bryan Yamamoto; Fiscal Year: 1992
    ....
  38. ANALYSIS OF STRIATAL SPECIFIC RGS9
    Michael Bannon; Fiscal Year: 2004
    ..Determine the cellular localization and dopaminergic regulation of RGS9 in the striatum. Specific Aim 2. Identify and analyze RGS signaling partners. Specific Aim 3. Analyze RGS9 targeting and function. ..
  39. DRUGS OF ABUSE EFFECTS ON BEHAVIORAL ORGANIZATION
    Martin Paulus; Fiscal Year: 1999
    ....
  40. Long-term effects of amphetamine on interval timing
    CLIVE WYNNE; Fiscal Year: 2003
    ..We believe, however, that there is no internal clock as such, and that drugs influence the perception of time by altering the perceived salience of the events used to delineate time intervals in experiments on timing. ..
  41. SYNTHESIS OF PROBES TO MONITOR BRAIN RECEPTOR MOBILITY
    JOHN NEUMEYER; Fiscal Year: 1990
    ..They may furthermore create novel methodologies in psycho- and neuropharmacology research...
  42. DOPAMINERGIC SIGNALING MODIFIES STRATIAL HISTONES
    Schahram Akbarian; Fiscal Year: 2009
    ....
  43. Dopaminergic modulation of frontostriatal function
    MARK D apos ESPOSITO; Fiscal Year: 2010
    ..abstract_text> ..
  44. BEHAVIORAL STUDIES ON NOVEL MONOAMINE UPTAKE INHIBITORS
    Srihari Tella; Fiscal Year: 2001
    ..Compounds with potential for the treatment of cocaine addiction are likely to result from this work. PROPOSED COMMERCIAL APPLICATION: Develop an effective treatment drug for cocaine addiction ..
  45. NEUROPHARMACOLOGICAL ALTERATIONS DURING PERIADOLESCENCE
    Martin Teicher; Fiscal Year: 2003
    ..abstract_text> ..
  46. Nucleus Accumbens Dopamine and Social Attachment
    BRANDON ARAGONA; Fiscal Year: 2002
    ..Finally, I will examine if mating increases dopamine release in the nucleus accumbens. Together these studies will further our understanding of how dopamine is involved in mammalian social attachment. ..
  47. Neural Mechanisms of Sequential Control
    MATTHEW MATELL; Fiscal Year: 2003
    ..The ability of dopaminergic drugs to alter both types of sequential behavior and the related neuronal activity will also be evaluated, in order to further develop treatment strategies for Parkinson's disease. ..
  48. LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS
    John Nutt; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  49. Pharmacotherapy for Minor Depression
    Robert Howland; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  50. Effect of enriched environment on ALS neurodegeneration
    Serge Przedborski; Fiscal Year: 2005
    ..This development/exploratory project offers an high-risk/high-yield set of studies which may demonstrate, in an original way, how environment may impact on the occurrence and the progression of ALS. ..
  51. Mechanisms of Bax-mediated cell death in the MPTP model
    Serge Przedborski; Fiscal Year: 2007
    ..Collectively, the proposed studies should shed light on the molecular mechanisms of neurodegeneration in PD and help to identify new molecular targets for therapeutic intervention. ..
  52. Nicotine and Cognition in Parkinsonism
    Jay Schneider; Fiscal Year: 2008
    ..Information obtained from these studies will hopefully lead to more efficient design of nicotinic therapeutics for patients with a variety of cognitive disorders. ..
  53. Multiple Factors Affecting Placebo Response in PD
    Christopher Goetz; Fiscal Year: 2004
    ..Defining these determinant influences will help enhance placebo responses in clinical practice and control them in clinical trials. ..
  54. NEURAL CIRCUITRY OF SENSORIMOTOR GATING ACROSS SPECIES
    Neal Swerdlow; Fiscal Year: 2006
    ....
  55. Calcitriol and Methamphetamine Neurotoxicity
    Wayne Cass; Fiscal Year: 2008
    ..Furthermore, if calcitriol is effective, it could have therapeutic applications in other disease processes where there is a loss of monoamine neurons, such as in Parkinson's disease. [unreadable] [unreadable] [unreadable]..
  56. PKC SIGNALING AND THE TREATMENT OF BIPOLAR DISORDER
    DONALD KUHN; Fiscal Year: 2002
    ....
  57. NITRIC OXIDE AND PROTEIN NITROTYROSINE IN THE MPTP MODEL
    Serge Przedborski; Fiscal Year: 2002
    ..This proposal contains a comprehensive set of experiments, which should provide important insights into the role of NO in MPTP toxicity. It should also shed light on the mechanism(s) of neurodegeneration in PD. ..
  58. Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
    Christopher H van Dyck; Fiscal Year: 2010
    ..This Pilot Clinical Trial will provide essential preliminary data for a subsequent full-scale trial of guanfacine for prefrontally-mediated cognitive dysfunction in elderly subjects. ..
  59. Calcitriol-Induced Restoration of Dopamine in a Model of Parkinson's Disease
    Wayne Cass; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  60. SYNUCLEIN AND NIGRAL DOPAMINERGIC NEURON DEGENERATION
    Serge Przedborski; Fiscal Year: 2003
    ....
  61. CORTICO-STRIATAL SUBSTRATES OF DEFICIENT STARTLE GATING
    Neal R Swerdlow; Fiscal Year: 2010
    ..New information from these studies will be a foundation for innovative models of the pathophysiology of schizophrenia and other inherited neuropsychiatric disorders, and for prospective strategies for novel drug development. ..
  62. AGING AND 6 HYDROXYDOPAMINE NEUROTOXICITY
    Wayne Cass; Fiscal Year: 2005
    ....